前蛋白转化酶枯草杆菌蛋白酶9及其抑制剂在动脉粥样硬化中的作用研究进展被引量：3

下载PDF

导出

摘要动脉粥样硬化(AS)严重威胁着人类的生命健康。低密度脂蛋白胆固醇通过促进泡沫细胞的形成及炎症反应在AS的发生、发展中发挥重要作用。低密度脂蛋白受体(LDLR)是负责清除血液中低密度脂蛋白(LDL)的主要分子之一。前蛋白转化酶枯草杆菌蛋白酶9(PCSK9)能够通过多种途径促进LDL介导的AS的发生和发展,其已被证实是治疗AS的重要靶点,目前已有多种类型的PCSK9抑制剂应用于AS的临床治疗或临床试验研究。本文综述了PCSK9的分子调节机制及其在AS中的作用,以及靶向PCSK9抑制剂的研究进展。

作者崔朝初卢娜冯超丽杨建波郭志坤王现伟

机构地区新乡医学院基础医学院

出处《新乡医学院学报》 CAS 2021年第3期213-219,共7页 Journal of Xinxiang Medical University

基金国家自然科学基金项目(编号:U1804166,81873459,81902442) 河南省高校科技创新人才计划项目(编号:19HASTIT004) 河南省杰出青年科学基金项目(编号:212300410012) 河南省优秀青年科学基金(编号:202300410309)。

关键词前蛋白转化酶枯草杆菌蛋白酶9 低密度脂蛋白受体胆固醇动脉粥样硬化心血管疾病

分类号 R56 [医药卫生—呼吸系统] X513 [环境科学与工程—环境工程]

引文网络
相关文献

参考文献5

1郭权,赵国安,林飞,刘懿,常峥峥,赵晖,阮梦瑶.河南北部人群血脂年龄乘积与冠状动脉粥样硬化性心脏病的相关性[J].新乡医学院学报,2020,37(8):734-738. 被引量：2
2李贵琦,周玉阳,法宪恩,万大国,刘雷,郭臣.氯雷他定对氧化型低密度脂蛋白诱导人血管内皮细胞黏附和炎症反应的影响[J].新乡医学院学报,2020,37(7):606-610. 被引量：3
3肖文虎,张红,彭湘萍,刘录山,姜志胜.PCSK9结构与功能[J].中国生物化学与分子生物学报,2009,25(3):213-218. 被引量：8
4Chenglin Wu,Cong Xi,Junhua Tong,Jing Zhao,Hualiang Jiang,Jiang Wang,Yiping Wang,Hong Liu.Design,synthesis,and biological evaluation of novel tetrahydroprotoberberine derivatives(THPBs) as proprotein convertase subtilisin/kexin type 9(PCSK9)modulators for the treatment of hyperlipidemia[J].Acta Pharmaceutica Sinica B,2019,9(6):1216-1230. 被引量：4
5Zhen-li Su,Peng-zhou Hang,Juan Hu,Yu-yang Zheng,Han-qi Sun,Jing Guo,Ke-yu Liu,Zhi-min Du.Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats[J].Acta Pharmacologica Sinica,2020,41(8):1085-1092. 被引量：19

二级参考文献38

1Chenglin Wu,Cong Xi,Junhua Tong,Jing Zhao,Hualiang Jiang,Jiang Wang,Yiping Wang,Hong Liu.Design,synthesis,and biological evaluation of novel tetrahydroprotoberberine derivatives(THPBs) as proprotein convertase subtilisin/kexin type 9(PCSK9)modulators for the treatment of hyperlipidemia[J].Acta Pharmaceutica Sinica B,2019,9(6):1216-1230. 被引量：4
2Peterson A S, Fong L G, Young S G, et al. PCSK9 function and physiology[J]. J Lipid Res, 2008, 48(7):1595-1599.
3Lagace T A, Curtis D E, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest,2006,116(11) : 2995-3005.
4Cunningham D, Danley D E, Geoghegan K F, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hyperoholesterolemia[ J]. Nat Struct Mol Biol, 2007,14(5) : 413-419.
5Gallagher T, Gilliland G, Wang L, et al. The prosegment-subtilisin BPN' complex: crystal structure of a specific " foldase" [ J ]. Structure, 1995,3(9) :907-914.
6Piper D E, Jackson S, Liu Q, et al. The crystal structure of PCSK9 : a regulator of plasma LDL-cholesterol [ J ]. Structure, 2007,15 (5) : 545-552.
7Sanchez J F, Lescar J, Chazalet V, et al. Biochemical and structural analysis of Helix pomatia agglutinin. A hexameric lectin with a novel fold[J]. J Biol Chem,2006,281(29):20171-20180.
8Zhang D W, Lagace T A, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation [ J]. J Biol Chem, 2007, 282 (25) : 18602-18612.
9Pokier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of LDLR and its closest family members VLDLR and APOER2[J]. J Biol Chem, 2008,283(4) : 2363-2372.
10Fisher T S, Lo Surdo P, Pandit S, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation[J]. J Biol Chem, 2007,282(28):20502-20512.